Washington Examiner
Sign in Subscribe
News
Politics
White House
Senate
House
Campaigns
Business
World
Investigations
Justice
Supreme Court
Crime
Entertainment
Washington Secrets
Policy
Defense
National Security
Energy and Environment
Education
Immigration
Finance and Economy
Healthcare
Foreign Policy
Tech
Infrastructure
Space
2026 Election
America at 250
IN FOCUS
Commentary
Columnists
Editorials
Think Tanks
Beltway Confidential
Op-Eds
Restoring America
Patriotism and Unity
Faith, Freedom, and Self-Reliance
Courage, Strength, and Optimism
Equality, Not Elitism
Community and Family
Fairness and Justice
Mission
Watch
Magazine
Magazine
Quarterly Briefing
Archives
Games
Sponsored
Protecting Air Ambulance Services
Powering Progress
ASAE – Association Leadership
National Parks
Examining Tax Reform
Fix TSCA
Inside the Corn Belt
Examining Transportation
Newsletters
Sign In Sign InHome
News
Politics
Policy2026 Election
Opinion
EditorialsOp-Eds
In FocusRestoring AmericaMagazineWatch
Sponsored
Protecting Air Ambulance ServicesPowering ProgressASAE – Association LeadershipNational ParksExamining Tax ReformFix TSCAInside the Corn BeltExamining Transportation
TWS Archive
Advertisement
Home › Tags › Posts tagged Pharmaceutical Industry

Tag: Pharmaceutical Industry

KaloBios Pharmaceuticals has filed for Chapter 11 bankruptcy on Wednesday. The biotech firm had ousted Martin Shkreli as its CEO earlier this month after he was arrested on federal charges of securities fraud. (AP Photo/Craig Ruttle) Healthcare

Arrested drug exec involved in Ponzi-like scheme, feds say

Robert King · December 17, 2015 6:49 pm
‘Most hated man’ in healthcare arrested Healthcare

‘Most hated man’ in healthcare arrested

Pete Kasperowicz · December 17, 2015 12:52 pm
Turing Pharmaceuticals CEO Martin Shkreli, who announced over the summer that his company would sell anti-malarial treatment Daraprim for 5,000 percent more after gaining its manufacturing license, is invited to testify. (Paul Taggart/Bloomberg) Healthcare

Lawmakers invite controversial drug executives to testify

Paige Winfield Cunningham · December 16, 2015 5:01 am
The biggest obstacle to congressional approval of TPP appears to be the deal's inadequate protection of intellectual property in "biologic" medicines. (Bloomberg News/Michael Fein) Healthcare

TPP trade agreement undercuts biologic patents

John Graham · December 15, 2015 5:01 am
During the first Senate hearing on high drug prices last week, senators from both parties lauded a solution that would speed approval of certain generic drugs. (AP Photo) Healthcare

Would speeding drug approvals knock down high prices?

Robert King · December 15, 2015 5:01 am
"We are looking at the House-passed bill, but we are also looking more broadly than that," she said. (Bloomberg/Andrew Harrer) Healthcare

Congress may take on high drug prices next year

Robert King · December 10, 2015 12:10 am
"I don't believe we should cast all pharmaceutical companies in the same light," said Sen. Thom Tillis, R-N.C., during a hearing of the Senate Special Committee on Aging on generic prices. (AP Photo/Jacquelyn Martin) Healthcare

GOP defends industry at drug price hearing

Robert King · December 9, 2015 9:40 pm
Local governments need naloxone as an antidote to heroin overdoses, but the price is soaring. (AP Photo/Mel Evans) Healthcare

High drug prices collide with efforts to stop overdoses

Robert King · December 9, 2015 5:01 am
"Democrats are ready to take action to address this crisis, but House Republicans are continuing to pretend it does not exist." (AP File Photo/Pablo Martinez Monsivais) Healthcare

Partisan attacks mark Dem drug price hearing

Robert King · December 3, 2015 5:01 am
In a new analysis, Kaiser and Georgetown University looked at 12 specialty drugs used to treat four diseases: cancer, hepatitis C, multiple sclerosis and rheumatoid arthritis. (AP Photo/Rafiq Maqbool) Healthcare

Seniors face high costs for pricey drugs

Robert King · December 2, 2015 6:20 pm
The drugs Harvoni and Sovaldi, made by Gilead, threw Medicare for a loop when they hit the market. Healthcare

Drug maker not concerned with ‘headlines’ on pricey drug

Robert King · December 2, 2015 5:01 am
Turing Pharmaceuticals and its CEO Martin Shkreli created a massive public backlash earlier this fall when the company hiked the price of Daraprim from $13.50 to $750 a pill. (AP Photo/Craig Ruttle) Healthcare

Pharma company cuts drug price after public backlash

Robert King · November 25, 2015 3:46 pm
Advertisement
  • ‹Previous page
  • 1
  • …
  • 119
  • 120
  • 121
  • 122
  • 123
  • …
  • 142
  • ›Next page
Page 121 of 142
Advertisement
Washington Examiner Manage Preferences

News

  • Politics
    • White House
    • Senate
    • House
    • Campaigns
  • Business
  • World
  • Investigations
  • Justice
  • Supreme Court
  • Crime
  • Washington Secrets
  • Entertainment
  • Sports

Policy

  • Defense
  • National Security
  • Energy
  • Immigration
  • Finance and Economy
  • Healthcare
  • Foreign Policy
  • Tech
  • Infrastructure
  • Space

Commentary

  • Columnists
  • Editorials
  • Think Tanks
  • Beltway Confidential
  • Op-Eds

Restoring America

  • Patriotism & Unity
  • Faith, Freedom & Self-Reliance
  • Courage, Strength & Optimism
  • Equality, Not Elitism
  • Community & Family
  • Fairness & Justice
  • Mission

Watch

  • Shows
NEWSLETTERS MAGAZINE ARCHIVE
  • Policies and Standards
  • Terms Of Service
  • Subscription Terms of Use
  • Privacy Policy
  • Your Privacy Choices
  • Transparency In Coverage
  • Advertise
  • Subscribe
  • Contact
  • Careers
  • Staff
  • About Examiner
  • Facebook
  • Twitter
© Copyright 2026. Washington Examiner. All Rights Reserved.
Advertisement